27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- Oncolytics Biotech Inc (NASDAQ: ONCY) has announced new data from Phase 2 trial evaluating pelareorep in combination with Merck & Co Inc (NYSE: MRK) Keytruda (pembrolizumab) in pancreatic cancer.
- Data will be presented at the 2021 American Society of Clinical Oncology Annual Meeting.
- Findings from the trial indicate that pelareorep and pembrolizumab synergize and show anti-cancer activity in patients who progressed after first-line treatment.
- Disease control was achieved in 42% (5/12) of patients, with one patient achieving a partial response and four patients achieving stable disease.
- On-treatment tumor biopsies showed pelareorep replication and increased infiltration of CD8+ T cells and PD-L1+ cells relative to pre-treatment samples.
- Patients achieving disease control showed reductions in pro-tumor regulatory T cells and increased activation of anti-cancer CD8+ T cells compared to those with progressive disease.
- Pelareorep-pembrolizumab combination therapy was found to be well tolerated, with most treatment-related adverse events being mild or moderate.
- Price Action: ONCY shares are up 5.8% at $2.99 during the market session on the last check Thursday.
- Related content: Benzinga's Full FDA Calendar
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!